Dharshini Sathishkumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dharshini Sathishkumar has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Chandana Shajil
Department of Dermatology, Venereology and Leprology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
8 shared publicationsMeera Thomas
Department of Pathology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
8 shared publicationsLydia Mathew
Department of Dermatology, Venereology and Leprology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
7 shared publicationsRenu George
Department of Dermatology (Retired) Christian Medical College and Hospital Vellore Tamil Nadu India
5 shared publications- Anju George
Department of Dermatology Christian Medical College Vellore Tamil Nadu India
4 shared publications Minu Jose Chiramel
Department of Dermatology, Venereology and Leprology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
4 shared publications
Latest Publications
- 9 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.
- 9 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.
- Open Access
- 27 February 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (2) , 263-269
Targeted Filaggrin Gene (FLG) Sequencing: A Pilot Study among Indian Children with Atopic Dermatitis
Background: Filaggrin deficiency causes early-onset atopic dermatitis (AD), extrinsic AD, persistent and severe disease, palmoplantar hyper linearity, keratosis pilaris, and increased risk of hand eczema. There is a paucity of data on the prevalence and types of variation in the filaggrin gene (FLG) in the Indian population. Aim and Objectives: To study the prevalence and characteristics of filaggrin mutations in Indian children affected with AD and to attempt a genotype-phenotype correlation. Materials and Methods: A pilot study was done among Indian children with AD aged 4-16 years, attending the Pediatric Dermatology outpatient department between February and September 2022 (7 months). Long-range polymerase chain reaction target enrichment and next-generation sequencing were used to sequence the complete FLG gene from peripheral blood samples. The identified variants were analyzed and categorized. Results: Among the 30 recruited children with AD, 28 genetic variants in exon 3 of FLG were found in 19 (63%) patients. These variants were classified as pathogenic (6, 21.4%), likely pathogenic (3, 10.7%), benign (16, 57.1%), and variant of uncertain significance (3, 10.7%). Among the 9 significant variants, 4 (45%) were novel. Although the patients with filaggrin variants had a higher prevalence of positive family history of atopy, other allergic diseases in the child, higher IgE levels, and a higher percentage of severe AD, the difference was not statistically significant. Limitation: Small sample size. Conclusion: Significant FLG null variants were identified in 23% (among which 45% were novel) of Indian children with AD. The spectrum of identified variants did not reflect the known FLG hotspots from other ethnicities, indicating the need for larger studies to determine the relevant hotspots in the Indian population.
- 27 February 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (2) , 263-269
Open AccessTargeted Filaggrin Gene (FLG) Sequencing: A Pilot Study among Indian Children with Atopic Dermatitis
Background: Filaggrin deficiency causes early-onset atopic dermatitis (AD), extrinsic AD, persistent and severe disease, palmoplantar hyper linearity, keratosis pilaris, and increased risk of hand eczema. There is a paucity of data on the prevalence and types of variation in the filaggrin gene (FLG) in the Indian population. Aim and Objectives: To study the prevalence and characteristics of filaggrin mutations in Indian children affected with AD and to attempt a genotype-phenotype correlation. Materials and Methods: A pilot study was done among Indian children with AD aged 4-16 years, attending the Pediatric Dermatology outpatient department between February and September 2022 (7 months). Long-range polymerase chain reaction target enrichment and next-generation sequencing were used to sequence the complete FLG gene from peripheral blood samples. The identified variants were analyzed and categorized. Results: Among the 30 recruited children with AD, 28 genetic variants in exon 3 of FLG were found in 19 (63%) patients. These variants were classified as pathogenic (6, 21.4%), likely pathogenic (3, 10.7%), benign (16, 57.1%), and variant of uncertain significance (3, 10.7%). Among the 9 significant variants, 4 (45%) were novel. Although the patients with filaggrin variants had a higher prevalence of positive family history of atopy, other allergic diseases in the child, higher IgE levels, and a higher percentage of severe AD, the difference was not statistically significant. Limitation: Small sample size. Conclusion: Significant FLG null variants were identified in 23% (among which 45% were novel) of Indian children with AD. The spectrum of identified variants did not reflect the known FLG hotspots from other ethnicities, indicating the need for larger studies to determine the relevant hotspots in the Indian population.
- Open Access
- 10 January 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (2) , 332-334
Prolonged Blistering Following Erythema Multiforme Major in a Child with COVID-19: A Twist in the Tale
- 10 January 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (2) , 332-334
Open AccessProlonged Blistering Following Erythema Multiforme Major in a Child with COVID-19: A Twist in the Tale
- 23 December 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (3) , 615-619
Vitamin D Dependent Rickets 2A With Alopecia: Three Cases With Novel Genetic Variants
Vitamin D‐dependent rickets type 2A (VDDR2A) is a rare cause of infantile‐onset alopecia, characterized by severe hypotrichosis, small cutaneous cysts, early‐onset treatment‐resistant rickets, and hypocalcemia. Alopecia, often starting a few weeks to months after birth, may be the presenting feature. We present three cases of VDDR2A with genetic variants in the vitamin D receptor (VDR) gene, their clinical features and biochemical parameters. This case series emphasizes that early identification of this rare cause of alopecia and treating the metabolic abnormalities can improve bone health.
- 23 December 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (3) , 615-619
Vitamin D Dependent Rickets 2A With Alopecia: Three Cases With Novel Genetic Variants
Vitamin D‐dependent rickets type 2A (VDDR2A) is a rare cause of infantile‐onset alopecia, characterized by severe hypotrichosis, small cutaneous cysts, early‐onset treatment‐resistant rickets, and hypocalcemia. Alopecia, often starting a few weeks to months after birth, may be the presenting feature. We present three cases of VDDR2A with genetic variants in the vitamin D receptor (VDR) gene, their clinical features and biochemical parameters. This case series emphasizes that early identification of this rare cause of alopecia and treating the metabolic abnormalities can improve bone health.
- Open Access
- 12 September 2024
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (3) , 462-465
Safety and Efficacy of Secukinumab in a Child with CARD14-Associated Papulosquamous Eruption: A Case Report and Review of Literature
- 12 September 2024
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (3) , 462-465
Open AccessSafety and Efficacy of Secukinumab in a Child with CARD14-Associated Papulosquamous Eruption: A Case Report and Review of Literature
- Open Access
- 30 August 2024
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 15 (5) , 770-778
Clinicopathological Profile of Pyoderma Gangrenosum: A 10-Year Retrospective Study from a Tertiary Care Center in South India
Background: Pyoderma gangrenosum (PG) is a reactive neutrophilic inflammatory dermatosis with a varied clinicopathologic presentation. It commonly manifests as rapidly progressive painful ulcers, mimicking varied conditions including infections, vasculitis, and malignancies, and is a diagnosis of exclusion. There are scarce data on PG from the Indian subcontinent. Aim and Objectives: The aim of the study was to study the clinicopathologic profile of patients with PG and their underlying systemic associations. Materials and Methods: A retrospective observational study was done between 2011 and 2021, and patients diagnosed as PG based on the diagnostic tool proposed by Maverakis et al. were recruited and their demographic, clinical, and histological findings were obtained. Results: Among 54 patients with suspected PG, 17 patients (eight males and nine females) fulfilled the diagnostic criteria, and the mean age of disease onset was 32.1 years (range: 3–60 years). Ulcerative variant was the most common type (9/17, 52.9%), and 29.4% had systemic associations including autoinflammatory syndromes. The onset at atypical sites such as face and hand were noted in one patient each. Histopathology revealed a polymorphous dermal infiltrate with neutrophilic predominance in the majority (94.1%). Systemic steroids (dose ranging from 0.5–1 mg/kg prednisolone equivalent) were used in 11/17 (64.7%) patients. The commonly used alternative drugs included clofazimine (47%), minocycline (29%), thalidomide (23.5%), adalimumab and mycophenolate mofetil in 17.6% each, dapsone and ciclosporine in 11.7% each. Remission was achieved between two weeks and three months in 10 (58.8%) patients after treatment initiation and two mortalities (11.7%) were recorded. Conclusion: PG can affect any age group and may be localized to rarer, atypical sites. The possibility of underlying autoinflammatory conditions should be considered in addition to the evaluation of other disorders like inflammatory bowel disease, hematological disorders, and rheumatological disorders.
- 30 August 2024
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 15 (5) , 770-778
Open AccessClinicopathological Profile of Pyoderma Gangrenosum: A 10-Year Retrospective Study from a Tertiary Care Center in South India
Background: Pyoderma gangrenosum (PG) is a reactive neutrophilic inflammatory dermatosis with a varied clinicopathologic presentation. It commonly manifests as rapidly progressive painful ulcers, mimicking varied conditions including infections, vasculitis, and malignancies, and is a diagnosis of exclusion. There are scarce data on PG from the Indian subcontinent. Aim and Objectives: The aim of the study was to study the clinicopathologic profile of patients with PG and their underlying systemic associations. Materials and Methods: A retrospective observational study was done between 2011 and 2021, and patients diagnosed as PG based on the diagnostic tool proposed by Maverakis et al. were recruited and their demographic, clinical, and histological findings were obtained. Results: Among 54 patients with suspected PG, 17 patients (eight males and nine females) fulfilled the diagnostic criteria, and the mean age of disease onset was 32.1 years (range: 3–60 years). Ulcerative variant was the most common type (9/17, 52.9%), and 29.4% had systemic associations including autoinflammatory syndromes. The onset at atypical sites such as face and hand were noted in one patient each. Histopathology revealed a polymorphous dermal infiltrate with neutrophilic predominance in the majority (94.1%). Systemic steroids (dose ranging from 0.5–1 mg/kg prednisolone equivalent) were used in 11/17 (64.7%) patients. The commonly used alternative drugs included clofazimine (47%), minocycline (29%), thalidomide (23.5%), adalimumab and mycophenolate mofetil in 17.6% each, dapsone and ciclosporine in 11.7% each. Remission was achieved between two weeks and three months in 10 (58.8%) patients after treatment initiation and two mortalities (11.7%) were recorded. Conclusion: PG can affect any age group and may be localized to rarer, atypical sites. The possibility of underlying autoinflammatory conditions should be considered in addition to the evaluation of other disorders like inflammatory bowel disease, hematological disorders, and rheumatological disorders.
- Open Access
- 26 June 2024
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 15 (4) , 605-611
Metabolic Comorbidities in Pediatric Psoriasis—A Comparative Cross-Sectional Study in South-Asian Children
Background: There is only limited data on the association between psoriasis and metabolic comorbidities in South-Asian children. Objective: To examine metabolic comorbidities among South-Asian children with and without psoriasis. Materials and Methods: A hospital-based, comparative, cross-sectional study was conducted in children with and without psoriasis over 19 months. Anthropometric, clinical, and metabolic comorbidity details (including disease extent and severity scores, obesity, systemic hypertension, diabetes mellitus, lipid abnormalities, and metabolic syndrome) were obtained in both groups according to standard criteria. Results: Fifty-eight children with psoriasis (25 males/33 females, age 11.3 ± 3.0 years, range 4 to 17 years) and 62 children without psoriasis (37 males/25 females, age 11.0 ± 3.6 years, range 4 to 18 years) were recruited. The prevalence of obesity (31.0% versus 14.5%, P = 0.031, odds ratio 2.65) and metabolic syndrome (18.6% versus 4.6%, P = 0.044, odds ratio 4.68) were higher in children with psoriasis than without. The prevalence of other metabolic comorbidities (systemic hypertension, pre-diabetes, lipid abnormalities, elevated serum alanine aminotransferase, and non-alcoholic fatty liver disease) was not different between children with and without psoriasis and between obese and non-obese children with psoriasis. Among children with psoriasis, those with abdominal obesity had significantly lower disease severity and extent scores than those without. Conclusion: Psoriasis is associated with a significantly higher prevalence of obesity and close to significantly higher prevalence of metabolic syndrome in South-Asian children. Screening for metabolic comorbidities is essential even in non-obese children with psoriasis. Disease extent and severity are less in obese compared to non-obese South-Asian children with psoriasis.
- 26 June 2024
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 15 (4) , 605-611
Open AccessMetabolic Comorbidities in Pediatric Psoriasis—A Comparative Cross-Sectional Study in South-Asian Children
Background: There is only limited data on the association between psoriasis and metabolic comorbidities in South-Asian children. Objective: To examine metabolic comorbidities among South-Asian children with and without psoriasis. Materials and Methods: A hospital-based, comparative, cross-sectional study was conducted in children with and without psoriasis over 19 months. Anthropometric, clinical, and metabolic comorbidity details (including disease extent and severity scores, obesity, systemic hypertension, diabetes mellitus, lipid abnormalities, and metabolic syndrome) were obtained in both groups according to standard criteria. Results: Fifty-eight children with psoriasis (25 males/33 females, age 11.3 ± 3.0 years, range 4 to 17 years) and 62 children without psoriasis (37 males/25 females, age 11.0 ± 3.6 years, range 4 to 18 years) were recruited. The prevalence of obesity (31.0% versus 14.5%, P = 0.031, odds ratio 2.65) and metabolic syndrome (18.6% versus 4.6%, P = 0.044, odds ratio 4.68) were higher in children with psoriasis than without. The prevalence of other metabolic comorbidities (systemic hypertension, pre-diabetes, lipid abnormalities, elevated serum alanine aminotransferase, and non-alcoholic fatty liver disease) was not different between children with and without psoriasis and between obese and non-obese children with psoriasis. Among children with psoriasis, those with abdominal obesity had significantly lower disease severity and extent scores than those without. Conclusion: Psoriasis is associated with a significantly higher prevalence of obesity and close to significantly higher prevalence of metabolic syndrome in South-Asian children. Screening for metabolic comorbidities is essential even in non-obese children with psoriasis. Disease extent and severity are less in obese compared to non-obese South-Asian children with psoriasis.
- Open Access
- 1 March 2024
- Published by Medknow in Indian Journal of Dermatology
- Vol. 69 (2) , 187-188
Disseminated Bacillus Calmette-Guerin Infection: The Harbinger of Severe Combined Immunodeficiency Disease
- 1 March 2024
- Published by Medknow in Indian Journal of Dermatology
- Vol. 69 (2) , 187-188
Open AccessDisseminated Bacillus Calmette-Guerin Infection: The Harbinger of Severe Combined Immunodeficiency Disease
- 17 January 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (3) , 518-522
Rapid recovery in a child with febrile ulceronecrotic Mucha‐Habermann disease following intravenous immunoglobulin administration
Febrile ulceronecrotic Mucha-Habermann disease (FUMHD), a lymphocyte-mediated inflammatory skin disorder, is considered a severe variant of pityriasis lichenoides et varioliformis acuta that can lead to a fatal outcome if not managed in a timely fashion. Children with FUMHD can have systemic complications involving various organs. The scarcity of reported cases and the absence of well-designed studies or randomized clinical trials to evaluate different therapeutic modalities pose a major challenge in treating this potentially life-threatening disorder. We report a five-year-old child with FUMHD and seizures treated unsuccessfully with a combination of systemic steroids, methotrexate, dapsone, and oral erythromycin, who improved rapidly and achieved disease control with just a single infusion of low-dose intravenous immunoglobulin.
- 17 January 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (3) , 518-522
Rapid recovery in a child with febrile ulceronecrotic Mucha‐Habermann disease following intravenous immunoglobulin administration
Febrile ulceronecrotic Mucha-Habermann disease (FUMHD), a lymphocyte-mediated inflammatory skin disorder, is considered a severe variant of pityriasis lichenoides et varioliformis acuta that can lead to a fatal outcome if not managed in a timely fashion. Children with FUMHD can have systemic complications involving various organs. The scarcity of reported cases and the absence of well-designed studies or randomized clinical trials to evaluate different therapeutic modalities pose a major challenge in treating this potentially life-threatening disorder. We report a five-year-old child with FUMHD and seizures treated unsuccessfully with a combination of systemic steroids, methotrexate, dapsone, and oral erythromycin, who improved rapidly and achieved disease control with just a single infusion of low-dose intravenous immunoglobulin.